Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ascendis Pharma AS (NASDAQ: ASND).

Full DD Report for ASND

You must become a subscriber to view this report.


Recent News from (NASDAQ: ASND)

Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30
COPENHAGEN, Denmark, May 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will hold a conference call and live webcas...
Source: GlobeNewswire
Date: May, 16 2018 16:20
Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP
Stock Monitor: Audentes Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Ascendis Pharma A/S (NASDAQ: ASND ), all you need to do is sign up now by clicking the following link www.active-investors.com/regi...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:25
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
FDA Ad Com Friday on trial design for achondroplasia
The FDA's Pediatric Advisory Committee will meet on Friday, May 11, to discuss the necessary design and objectives for clinical trials of drugs to treat achondroplasia , a rare inherited bone growth disorder characterized by dwarfism. More news on: Ascendis Pharma, BioMarin Pharmaceutic...
Source: SeekingAlpha
Date: May, 09 2018 15:44
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP
- TransCon CNP is Company’s Third Product Candidate in Clinic - COPENHAGEN, Denmark, May 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, ann...
Source: GlobeNewswire
Date: May, 08 2018 07:00
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
COPENHAGEN, Denmark, May 07, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced an upcoming poster presentation on the phase 1 trial for its Tran...
Source: GlobeNewswire
Date: May, 07 2018 16:05
Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Macro matters: Traders are back to focusing on economic reports after no major deve...
Source: SeekingAlpha
Date: May, 05 2018 08:33
Institutional Top Ideas Series: DAFNA Capital Management
In the last entry of this recently rebooted series, we took a look at top ideas from Broadfin Capital (whose performance more than doubled that of the IBB during time frame we looked at). Going forward, I hope to continue delve into the portfolios of successful hedge funds predominantly ...
Source: SeekingAlpha
Date: April, 13 2018 01:03
Consolidated Research: 2018 Summary Expectations for Ternium S.A, CNB Financial, Barrick Gold, New York Mortgage Trust, Ascendis Pharma A/S, and Fiat Chrysler Automobiles N.V - Fundamental Analysis, Key Performance Indications
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ternium S.A. (NYSE:TX), CNB Financial Corporation (NASDAQ:CCNE), Barrick...
Source: GlobeNewswire
Date: April, 11 2018 07:50
Wired News - Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis
Stock Monitor: Ascendis Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 04, 2018 / Active-Investors.com has just released a free research report on Synlogic, Inc. (NASDAQ: SYBX ). If you want access to this report all you need to do is sign up now by clicking the follo...
Source: ACCESSWIRE IA
Date: April, 04 2018 07:10

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1767.3566.9268.3866.710665,018
2017-06-2023.4022.8223.6421.95140,505
2017-06-1923.7324.0525.1223.05822,443
2017-06-1623.4224.0024.3922.9554,135
2017-06-1522.8023.2023.8422.42505,496

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1715,88425,04163.4320Short
2018-08-1650,76868,35974.2667Short
2018-08-1537,42683,48444.8301Short
2018-08-1452,474109,65847.8524Short
2018-08-134,95049,27110.0465Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ASND.


About Ascendis Pharma AS (NASDAQ: ASND)

Logo for Ascendis Pharma AS (NASDAQ: ASND)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ASND)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 03 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 01 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 12 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 28 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 28 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 15 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: March, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 26 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: February, 23 2018

       

       


      Daily Technical Chart for (NASDAQ: ASND)

      Daily Technical Chart for (NASDAQ: ASND)


      Stay tuned for daily updates and more on (NASDAQ: ASND)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ASND)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ASND is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ASND and does not buy, sell, or trade any shares of ASND. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/